These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9316670)

  • 21. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S; Vérin M
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
    Nutt JG; Carter JH
    Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apomorphine in the treatment of Parkinson's disease.
    Hagell P; Odin P
    J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine agonists in Parkinson's disease: a look at apomorphine.
    Lees AJ
    Fundam Clin Pharmacol; 1993; 7(3-4):121-8. PubMed ID: 8500783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
    Marco AD; Appiah-Kubi LS; Chaudhuri KR
    Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
    Carbone F; Djamshidian A; Seppi K; Poewe W
    CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid treatment of "wearing off" in Parkinson's disease.
    Swope DM
    Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
    Widnell KL; Comella C
    Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.